Common use of Biosimilar Product Clause in Contracts

Biosimilar Product. If a Licensed Product is generating Net Sales in a region during the applicable Royalty Term at a time when a Biosimilar Product with respect to such Licensed Product is being sold in such region, then the royalty rate applicable to Net Sales of such Licensed Product in such region in such Calendar Quarter shall be reduced by the following percentage of the royalty rate that would otherwise be owed on such Net Sales of such Licensed Product in such region under Section 9.3(a), for so long as the Biosimilar Product is being sold in such region during the Royalty Term: [***].

Appears in 2 contracts

Samples: License and Collaboration Agreement (Five Prime Therapeutics Inc), License and Collaboration Agreement (Zai Lab LTD)

AutoNDA by SimpleDocs

Biosimilar Product. If a Licensed Product is generating Net Sales in a region country during the applicable Royalty Term at a time when a Biosimilar Product with respect to such Licensed Product is being sold in such regioncountry, then the royalty rate applicable to Net Sales of such Licensed Product in such region country in such Calendar Quarter shall be reduced by the following percentage to *** of the royalty rate that would otherwise be owed on such applicable to the Net Sales of such Licensed Product in such region country under Section 9.3(a7.3(a)(i), for so long as the Biosimilar Product is being sold in such region during the Royalty Term: [***]country.

Appears in 1 contract

Samples: License and Collaboration Agreement (Five Prime Therapeutics Inc)

AutoNDA by SimpleDocs

Biosimilar Product. If (A) a Licensed Product is generating Net Sales in the Field in a region country in the Territory during the applicable Royalty Term at a time when a Biosimilar Product with respect to such Licensed Product is being sold in such regioncountry; and (B) the market share of the Biosimilar Product(s) in such country [***], then then, subject to Section 9.5(c)(iv), the royalty rate applicable to Net Sales of such Licensed Product in such region country in such Calendar Quarter shall be reduced by the following percentage of the royalty rate that would otherwise be owed on such Net Sales of such Licensed Product in such region under Section 9.3(a), for so long as the Biosimilar Product is being sold in such region during the Royalty Term: [***]..83

Appears in 1 contract

Samples: Exclusive Option and License Agreement (Leap Therapeutics, Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.